THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THIS WARRANTCommon Stock Purchase Warrant • August 15th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on February 17, 2015, 500,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THIS WARRANTCommon Stock Purchase Warrant • August 15th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on February 17, 2015, 500,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
Amendment to the Clinical Trial AgreementClinical Trial Agreement • August 15th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances)
Hadasit Medical Research Services and Development Ltd., (“Hadasit” or the “Institution”) and Prof. Dimitrios Karousis (the “Investigator”) on one hand, and BrainStorm Cell Therapeutics Ltd. (“Sponsor”),
BrainStorm Cell Therapeutics Inc. Restricted Stock Agreement Granted Under 2005 U.S. Stock Option and Incentive PlanRestricted Stock Agreement • August 15th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made as of the [___] day of [_________], 201[__] (the “Grant Date”) between BrainStorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and [__________] (the “Participant”).
BRAINSTORM CELL THERAPEUTICS INC. OPTION AGREEMENT Made effective as of the __ day of___ 2011Option Agreement • August 15th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances)
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • August 15th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances)
This agreement (hereinafter: “Agreement”) is entered into as of February 17, 2010 (hereinafter: the “Effective Date”) by and between Hadasit Medical Research Services and Development Ltd., a company duly incorporated under the laws of Israel I.D. No. 51-115685-3, from Jerusalem Bio-Park, Hadassah Ein-Kerem Medical Center, P.O.Box 12000, Jerusalem 91120, (hereinafter: “Hadasit” or the “Institution”) and Prof. Dimitrios Karousis (the “Investigator”) on one hand and BrainStorm Cell Therapeutics Ltd., a corporation organized under the laws of Israel I.D. No. 51-360102-1, with its registered office located at 12 Basel Street, Petah-Tikva 49001, in this matter duly represented by Rami Efrati, (hereinafter: “Sponsor”), on the other hand.
